Who can safely evade a magnetic resonance imaging fusion-targeted biopsy (MRIFTB) for prostate imaging reporting and data system (PI-RADS) 3 lesion?
Myong KimHoyoung RyuHak Jong LeeSung Il HwangGheeyoung ChoeSung Kyu HongPublished in: World journal of urology (2020)
Men with the PI-RADS 3 lesion and low PSA density might safely evade the MRIFTB, regardless of age or prior biopsy history.
Keyphrases
- prostate cancer
- magnetic resonance imaging
- ultrasound guided
- fine needle aspiration
- high resolution
- radical prostatectomy
- electronic health record
- computed tomography
- adverse drug
- middle aged
- big data
- benign prostatic hyperplasia
- contrast enhanced
- emergency department
- machine learning
- data analysis
- fluorescence imaging
- drug induced